Osteoblasts in prostate cancer metastasis to bone

被引：451

作者：

Logothetis, CJ

Lin, SH

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Oncol, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA

来源：

NATURE REVIEWS CANCER | 2005年 / 5卷 / 01期

关键词：

D O I：

10.1038/nrc1528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastasis to bone is common in lung, kidney, breast and prostate cancers. However, prostate cancer is unique in that bone is often the only clinically detectable site of metastasis, and the resulting tumours tend to be osteoblastic ( bone forming) rather than osteolytic (bone lysing). The interaction between host cells and metastatic cancer cells is an important component of organ-specific cancer progression. How can this knowledge lead to the development of more effective therapies?

引用

收藏

页码：21 / 28

页数：8

相关论文

共 84 条

[61] Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin [J].

Orford, K ;

Crockett, C ;

Jensen, JP ;

Weissman, AM ;

Byers, SW .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :24735-24738

[62] Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development [J].

Otto, F ;

Thornell, AP ;

Crompton, T ;

Denzel, A ;

Gilmour, KC ;

Rosewell, IR ;

Stamp, GWH ;

Beddington, RSP ;

Mundlos, S ;

Olsen, BR ;

Selby, PB ;

Owen, MJ .

CELL, 1997, 89 (05) :765-771

[63]

Pinthus JH, 2000, CANCER RES, V60, P6563

[64] A COMPARISON OF THE PALLIATIVE EFFECTS OF SR-89 AND EXTERNAL-BEAM RADIOTHERAPY IN METASTATIC PROSTATE-CANCER [J].

QUILTY, PM ;

KIRK, D ;

BOLGER, JJ ;

DEARNALEY, DP ;

LEWINGTON, VJ ;

MASON, MD ;

REED, NSE ;

RUSSELL, JM ;

YARDLEY, J .

RADIOTHERAPY AND ONCOLOGY, 1994, 31 (01) :33-40

[65] AN AMINO-TERMINAL FRAGMENT OF UROKINASE ISOLATED FROM A PROSTATE-CANCER CELL-LINE (PC-3) IS MITOGENIC FOR OSTEOBLAST-LIKE CELLS [J].

RABBANI, SA ;

DESJARDINS, J ;

BELL, AW ;

BANVILLE, D ;

MAZAR, A ;

HENKIN, J ;

GOLTZMAN, D .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (03) :1058-1064

[66] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Chen, B .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) :1458-1468

[67] Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer [J].

Sartor, O ;

Reid, RH ;

Hoskin, PJ ;

Quick, DP ;

Ell, PJ ;

Coleman, RE ;

Kotler, JA ;

Freeman, LM ;

Olivier, P .

UROLOGY, 2004, 63 (05) :940-945

[68] Preoperative plasma levels of transforming growth factor beta1 (TGF-β1) strongly predict progression in patients undergoing radical prostatectomy [J].

Shariat, SF ;

Shalev, M ;

Menesses-Diaz, A ;

Kim, IY ;

Kattan, MW ;

Wheeler, TM ;

Slawin, KM .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2856-2864

[69] ISOLATION OF A HUMAN PROSTATE CARCINOMA CELL LINE (DU 145) [J].

STONE, KR ;

MICKEY, DD ;

WUNDERLI, H ;

MICKEY, GH ;

PAULSON, DF .

INTERNATIONAL JOURNAL OF CANCER, 1978, 21 (03) :274-281

[70] Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover [J].

Street, J ;

Bao, M ;

deGuzman, L ;

Bunting, S ;

Peale, FV ;

Ferrara, N ;

Steinmetz, H ;

Hoeffel, J ;

Cleland, JL ;

Daugherty, A ;

van Bruggen, N ;

Redmond, HP ;

Carano, RAD ;

Filvaroff, EH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :9656-9661

← 1 2 3 4 5 6 7 8 9 →